Efficacy of a psma-targeted nanoparticle

Access through your institution Buy or subscribe Following a phase I dose-finding study, the phase II trial evaluated BIND-014 (60 mg/m2 every 21 days with prednisone) in 42

chemotherapy-naive patients with mCRPC who progressed on antiandrogen therapy. The primary end point was radiographic progression-free survival (rPFS), and secondary end points included PSA

response and circulating tumour cell (CTC) conversion (defined as a change from baseline of ≥5 to <5 CTCs per 7.5 ml of blood). After a median of 6 treatment cycles, 12 of 40 (30%)

patients with evaluable data had a ≥50% PSA decline, and CTC conversion occurred in 13 of 26 (50%) patients. Of the 19 patients with measurable disease, 9 (47%) patients had stable disease,

5 (26%) had partial responses, and 1 (0.05%) had a complete response. Importantly, median rPFS was 9.9 months and 26 of 40 patients (65%) experienced an rPFS of ≥6 months. This is a preview

of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value

online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more

Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS:

* Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Autio, K. A. et al. Safety and efficacy of BIND-014, a docetaxel

nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer. _JAMA Oncol._ https://doi.org/10.1001/jamaoncol.2018.2168 (2018)

Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Urology http://www.nature.com/nrurol/ Conor A. Bradley Authors * Conor A.

Bradley View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Conor A. Bradley. RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Bradley, C.A. Efficacy of a PSMA-targeted nanoparticle. _Nat Rev Urol_ 15, 590–591 (2018). https://doi.org/10.1038/s41585-018-0067-0 Download

citation * Published: 26 July 2018 * Issue Date: October 2018 * DOI: https://doi.org/10.1038/s41585-018-0067-0 SHARE THIS ARTICLE Anyone you share the following link with will be able to

read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative